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Abstract
Background: Intradialytic hypotension (IDH) is a common clinical manifestation associated with poor prognosis in
hemodialysis (HD) patients. HD patients who suffer from diabetic nephropathy (DN) are increasing and diabetes is a
major cause of IDH. Effective interventional treatments for IDH have yet to be fully evaluated. The aim of this
multicenter prospective study is to clarify the effect of biocompatible hydrophilic polymer-coated polysulfone (PS)
membrane, TORAYLIGHT® NV (NV) dialyzers on IDH.
Methods: This is a prospective stratified-randomized multicenter trial. Forty DN patients undergoing HD and
receiving two or more times of treatments for IDH per month were enrolled in this study. They were stratified by
the number of treatments for IDH and divided to two groups using NV or conventional PS/polyethersulfone (PES)
dialyzers. The number of treatments for IDH and changes in systolic blood pressure (SBP) were monitored for
6 months. Patients’ demographic and clinical characteristics were also collected at enrollment and the last month
of the observation period. In order to clarify the patient characteristics that induced preferable effects by using NV
dialyzers, responders were defined as the patients whose average SBP falls in 1 month improved from over
30 mmHg to no more than 30 mmHg.
Results: The total number of treatments for IDH decreased significantly in NV group, even though pre-dialysis body
weight and ultrafiltration volume were similar. In addition, patients using NV had significantly higher post-dialysis
SBP and the lowest SBP during HD at sixth month compared as those in PS/PES group. NV responders had valuables
suggesting malnutrition and microinflammation, and better lipid profiles than non-responders. However, the representative
markers related to nutritional status, arteriosclerosis, and inflammation were not improved by NV treatment.
Conclusions: NV had preferable effects on IDH in DN HD patients. Our results suggest the usefulness of NV as a possible
method to deal with IDH. Further studies are needed to clarify the mechanism of NV effects on hemodynamic status.
Trial registration: This study was registered on September 26, 2013, in the University Hospital Medical Information
Network-Clinical Trials Registry in Japan (Study ID: UMIN000011872).
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Background
Intradialytic hypotension (IDH) is a common side effect in
hemodialysis (HD) patients and occurs in approximately
30% of all HD sessions [1]. IDH is caused by failure in the
compensation of reduced circulating blood volume, and is
associated with increased mortality [2–4]. Several patient-
related characteristics and comorbidities increase the risk of
IDH, mainly through impairment of the counter-regulatory
cardiovascular hemodynamic and neuro-hormonal mecha-
nisms, such as age and diabetes [5]. HD patients are getting
older, and diabetes nephropathy (DN) is the major primary
disease of HD in Japan [6]. Therefore, IDH-prone patients
are also increasing. Several studies of the interventional
effects on IDH include comparison of the dialysate compo-
nents such as sodium and acetic acid [7, 8], and difference of
treatment methods [9]. However, few studies investigated the
advantage of new dialyzer over conventional dialyzers to deal
with IDH [10].
Recently, the state of water molecules in the vicinity of
a membrane was reported to play an important role in
the biocompatibility of synthetic polymer membranes
[11]. A new polysulfone (PS) membrane dialyzer, TOR-
AYLIGHT® NV (NV) (Toray Industries Inc., Tokyo,
Japan), was developed by focusing on the state of water
molecules on the membrane surface [12]. Yamaka et al.
confirmed that platelet adhesion to the membrane
surface of NV after HD was less than that of conven-
tional PS dialyzers [13]. Ronco et al. showed that more
patients in NV group reached heparin-free dialysis with-
out clotting events during the heparin reduction test,
suggesting anti-thrombogenic effects of the NV dialyzers
as compared to conventional dialyzers [14]. Hidaka et al.
reported that 3-month use of NV reduced the level of
platelet-derived microparticles (PDMPs) in HD patients
[15]. PDMPs are significantly increased in many
prothrombotic diseases, including diabetes, cardiovascu-
lar disease and uremia [16, 17], which contribute to the
development and progression of atherosclerosis [18]. In
summary, improved biocompatibility provides some
preferable effects on the maintenance of blood vessels,
especially in patients with atherosclerosis.
Therefore, in this study, we investigated whether
“biocompatible” hydrophilic polymer-coated PS dialyzers
improve IDH in HD patients with DN compared as
conventional PS/polyethersulfone (PES) dialyzers. In
addition, to analyze the effects of “biocompatible” dia-
lyzers on IDH, we also evaluated clinical and serological
parameters of anemia, mineral-bone disorder, nutritional
status, lipid profile, arteriosclerosis, and inflammation.
Methods
Study design and subjects
This study was designed as a prospective stratified-
randomized multicenter trial. Six dialysis centers participated
in this study. IDH was defined as systolic blood pressure
(SBP) fall over 20 mmHg from baseline, or presentation of
symptoms such as unconsciousness, nausea, chest discom-
fort, and muscle cramps associated with hypotension requir-
ing any medical interventions [19]. We performed the
following treatments for IDH: (1) saline administration, over
100 mL at one time; (2) decrease of ultrafiltration rate; (3)
interruption of ultrafiltration; (4) extracorporeal ultrafiltra-
tion method; (5) dialysis discontinuation; (6) leg elevation;
and (7) vasopressor administration [20].
Study flow diagram is shown in Fig. 1. The subjects
enrolled in this study were DN patients aged between 20
and 80 years with more than 1-year HD vintage using
PS, PES, or polyester-polymer alloy (PEPA) dialyzers,
who received two or more times of treatments for IDH
in 1 month. Exclusion criteria were as follows: (i) treat-
ment by the other renal insufficiency therapies, such as
continuous ambulatory peritoneal dialysis and hemodia-
filtration; (ii) enrollment in the other clinical study; (iii)
anamnestic cardiovascular diseases (heart attack, stroke)
within less than 3 months; and (iv) pregnancy, infectious
disease, cancer, or acute inflammation. First, in “patient-
selection period,” the number of IDH treatments for
each enrolled patient was counted. Then, they were
stratified by the number of IDH treatments and
allocated to two groups, called NV and PS/PES group.
Second, in “pre-observation period” (zero month), the
patients’ demographic and clinical characteristics were
collected. The values of ejection fraction, comorbidities,
and antiplatelet/anticoagulant medications in six cases
were unavailable because of lack of recent echocardiog-
raphy data and uncertainty of patient’s statements. The
number of IDH treatments was counted continuously.
Third, in “comparative period” (first to sixth month),
dialyzers in NV group were changed to NV and both
groups were observed for 6 months. The dialyzers used
are shown in Additional files 1 and 2.
There were no differences in dialysis conditions (blood
flow rate, dialysate flow rate, dialysis time) including
sodium concentration of dialysis fluid between NV and
PS/PES groups during the whole study period (from zero
to sixth month) (data not shown).
Primary outcome
Primary outcome was the average of the total number of
IDH treatments performed in 1 month, expressed as
“total number (times/month/patient)” in each group.
Besides, pre-dialysis SBP, post-dialysis SBP, the lowest
SBP during HD, SBP fall, pre-dialysis body weight, and
ultrafiltration volume were measured in each dialysis
session for 1 month and the average value was analyzed.
In addition, in order to analyze the characteristics of
responders to the dialyzer treatment, we sought the ref-
erences to find out the cutoff value of average SBP fall
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in 1 month that was related to prognosis. However, there
is no consensus, evidence-based medical definition for
IDH which is related to prognosis [21]. Therefore, we
referred to a previous paper investigating the relation-
ship of IDH with mortality in Japanese HD patients re-
ported by Shoji et al. [2]. Shoji et al. described that a
greater fall in SBP was associated with increased mortal-
ity. This relationship was most clearly demonstrated
when the cutoff point for the fall in SBP was set at
40 mmHg (greater fall: 40 mmHg or greater, smaller fall:
less than 39 mmHg). The impact of the intradialytic fall
in SBP on mortality was independent of the pre-dialysis
SBP. However, Shoji et al. recorded SBP within a single
HD session that was the first session of the week, which
was different from average SBP fall in 1 month evaluated
in our analysis. Shoji et al. also reported that the mean
intradialytic falls in SBP in the patients who died and
those who survived were about 28 and 32 mmHg, re-
spectively. Therefore, the cutoff point for average SBP
fall in 1 month at 30 mmHg is reasonable considering
the results reported by Shoji et al. Moreover, Chou et al.
reported that intradialytic SBP change of less than
15 mmHg and more than 50 mmHg had poor prognosis
compared with intradialytic SBP change of 21 to
30 mmHg by analyzing a US-based cohort of 112,013
incident patients over a 5-year period [22]. Conse-
quently, another outcome was defined as the improve-
ment of average SBP fall in 1 month from over
30 mmHg at zero month to no more than 30 mmHg at
sixth month. The parameters that strongly associate with
IDH such as cardiothoracic ratio (CTR) and the number
of antihypertensive drug users were also examined.
Blood pressure was measured by oscillometric method.
Secondary outcome
The following items were evaluated in the beginning of pre--
observation period (zero month) and sixth month to clarify
the effects of dialyzers: “Nutritional status” (body mass index,
albumin); “blood cell count” (white blood cell, platelet);
“anemia management” (hemoglobin, the number of
erythropoiesis-stimulating agent users, ferritin); “mineral-
bone disorder control” (phosphate, calcium, intact-
parathyroid hormone); “lipid” (total cholesterol, triglyceride,
high-density lipoprotein cholesterol); “arteriosclerosis and
inflammation” (ankle brachial index, homocysteine, pentosi-
dine, high-sensitivity C-reactive protein (hsCRP), pentraxin 3
(PTX3)); and “catecholamine” (adrenaline, noradrenaline,
dopamine). Serum homocysteine and pentosidine levels were
measured by HPLC assay. hsCRP and PTX3 was measured
by latex enhanced immunoturbidimetric assay and ELISA,
Enrollment of patients (n=44) 
Diabetic nephropathy, dialysis vintage:  one year 
Hemodialysis using PS/PES/PEPA dialyzers 
Treatments for intradialytic hypotension:  two times per month 
Patient-selection period (one month) 
Hemodialysis using PS/PES/PEPA dialyzers
Counting the number of treatments for intradialytic hypotension 
Stratified allocation by the number of treatments for intradialytic hypotension  
NV group (n=22) PS/PES group (n=22)
Pre-observation period (one month) 
Hemodialysis using PS/PES/PEPA dialyzers
Counting the number of treatments for intradialytic hypotension 
Collecting demographic and clinical characteristics 
Comparative period between two groups (six months) 
NV group: NV dialyzers 
PS/PES group: PS/PES dialyzers 
Counting the number of treatments for intradialytic hypotension 
Collecting clinical characteristics at sixth month
NV group (n=20) 
analyzed






Fig. 1 Study flow diagram. Forty patients completed the entire comparative period. There were two withdrawals from each group (NV group: one
moved and the other received a surgical treatment. PS/PES group: one moved and the other changed the modality from HD to hemodiafiltration)
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respectively. The analyses of homocysteine, pentosidine,
hsCRP, PTX3, and catecholamine were entrusted to LSI
Medience Corporation (Tokyo, Japan). Ankle brachial index
was measured by oscillometric method.
Statistical analysis
All values are expressed as mean ± SD. Statistical
analysis was performed using SPSS for Windows version
13.0 (SPSS, Inc., Chicago, IL, USA). Variables such as
SBP, the number of treatments for IDH between NV and
PS/PES groups were compared using Student’s t test or
Welch’s t test, if data were normally distributed. Non--
normally distributed data were analyzed by Man-Whit-
ney’s U test. Prevalence data were analyzed by means of
chi-square or Fisher’s exact probability test. The changes
of serological and clinical parameters in the time course
of treatment were analyzed using paired t test or Wil-
coxon signed-ranks test, as appropriate. Time-dependent
changes of the parameters were compared using
repeated-measures analysis of variance or Friedman’s
test, followed by a post hoc test. Significance was defined
by P less than 0.05.
Results
Subject characteristics
Of the 44 enrolled patients in six dialysis centers, 40
patients (n = 20 each for NV and PS/PES groups) com-
pleted the entire comparative period. There were two
withdrawals from each group (NV group: one moved
and the other received a surgical treatment. PS/PES
group: one moved and the other changed the modality
from HD to hemodiafiltration.). There were no signifi-
cant differences in the demographic and clinical charac-
teristics of the patients between two groups, except the
number of antihypertensive drug users and the value of
ejection fraction. Patients in NV group had more
difficulty to control blood pressure and better ejection
fraction values than ones in PS/PES group (Table 1).
There was one patient who took a vasopressor drug in
NV group (data not shown).
Changes in the number of treatments for IDH
As shown in Fig. 2a, the total number of treatments was
not statistically different between NV and PS/PES groups
during the whole study period. However, in NV group, it
decreased significantly at fifth and sixth month, com-
pared with that in pre-observation period. In contrast, in
PS/PES group, the total number of treatments did not
decrease significantly.
The number of each treatment is shown in Fig. 2b–h.
In NV group, the number of every treatment decreased
at sixth month compared to that in pre-observation
period. Especially, the number of dialysis discontinuation
and leg elevation decreased significantly at fifth and
sixth month. Conversely, in PS/PES group, the numbers
of some treatments such as decrease of ultrafiltration
rate and dialysis discontinuation increased and the
others such as saline administration and leg elevation
decreased. In addition, one patient who took a vasopres-
sor drug in NV group could stop the medication during
the study period.
Table 1 Demographic and clinical characteristics of the patients
enrolled
NV group PS/PES group P
Patients (n) 20 20
Age (years) 62.3 ± 9.1 61.5 ± 10.1 0.78
Female (%) 7 (35%) 6 (30%) 0.74
Dialysis vintage (years) 9.2 ± 4.8 6.7 ± 4.5 0.11
Antihypertensive drug users (%) 16 (80%) 9 (45%) 0.02
Antiplatelet/anticoagulant
users (%)a
14 (82%) 17 (100%) 0.23
Ejection fraction (%)a 70.4 ± 5.2 60.7 ± 8.0 < 0.01
Comorbidities
Ischemic heart disease (%)a 7 (41%) 12 (71%) 0.17
Heart failure (%)a 6 (35%) 5 (29%) 1.00
Cerebral infarction (%)a 3 (18%) 2 (12%) 1.00
Cerebral hemorrhage (%)a 0 (0%) 1 (6%) 1.00
BMI (kg/m2) 24.0 ± 5.0 24.9 ± 4.3 0.57
White blood cell count (×103/μL) 6.3 ± 1.8 6.6 ± 2.7 0.53
Hemoglobin (g/dL) 11.2 ± 0.8 11.0 ± 2.6 0.66
Platelet (×104/μL) 20.0 ± 5.2 18.5 ± 4.9 0.35
ESA user (%) 13 (65%) 10 (50%) 0.34
Ferritin (ng/mL) 122.4 ± 141.4 94.2 ± 53.8 0.41
Phosphate (mg/dL) 5.6 ± 1.5 5.4 ± 1.6 0.72
Calcium (mg/dL) 9.1 ± 0.7 8.8 ± 0.6 0.20
Intact PTH (ng/mL) 122 ± 98 162 ± 163 0.34
Albumin (g/dL) 3.5 ± 0.3 3.5 ± 0.3 0.78
Total-cholesterol (mg/dL) 171 ± 36 154 ± 28 0.10
Triglyceride (mg/dL) 124 ± 70 142 ± 86 0.49
HDL-cholesterol (mg/dL) 44 ± 14 44 ± 15 0.96
Ankle brachial index (right) 1.03 ± 0.25 1.09 ± 0.28 0.51
Ankle brachial index (left) 1.11 ± 0.19 1.12 ± 0.26 0.91
Homocysteine (nmol/mL) 35.8 ± 25.1 34.7 ± 18.5 0.87
Pentosidine (μg/mL) 0.415 ± 0.218 0.326 ± 0.108 0.11
hsCRP (mg/dL) 0.221 ± 0.174 0.187 ± 0.196 0.57
Pentraxin 3 (ng/mL) 4.04 ± 1.68 4.55 ± 3.76 0.58
Adrenaline (ng/mL) 0.02 ± 0.01 0.02 ± 0.01 0.10
Noradrenaline(ng/mL) 0.33 ± 0.19 0.38 ± 0.19 0.46
Dopamine (ng/mL) 0.04 ± 0.02 0.05 ± 0.02 0.13
BMI body mass index, ESA erythropoiesis-stimulating agent, HDL high-density
lipoprotein, hsCRP high-sensitivity C-reactive protein
an = 17 in both NV and PS/PES groups
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Changes in SBP
Pre-dialysis SBP, post-dialysis SBP, the lowest SBP and
SBP fall were also monitored continuously (Fig. 3). In
pre-observation period, there were no differences in pre-
dialysis, post-dialysis, the lowest SBP and SBP fall
between NV and PS/PES groups. However, in NV group,
post-dialysis and the lowest SBP were significantly
higher at sixth month compared as those in PS/PES
group. As for SBP fall, the average value was significantly
relieved in NV group at sixth month compared as that
in pre-observation period, while SBP fall was not
improved in PS/PES group. Besides, the number of
patients whose average SBP fall over 30 mmHg in
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Fig. 2 The number of treatments for intradialytic hypotension in NV and PS/PES groups. a The total number of treatments was not significantly
different between NV and PS/PES groups during the whole study period. However, in NV group, it decreased significantly compared with that in
pre-observation period. In contrast, in PS/PES group, the total number of treatments did not decrease significantly. b–h In NV group, the number
of every treatment decreased at sixth month compared as that in pre-observation period. Especially, the number of dialysis discontinuation and
leg elevation decreased significantly at fifth and sixth month. Conversely, in PS/PES group, the number of some treatments such as decrease of
ultrafiltration rate and dialysis discontinuation increased and the others such as saline administration and leg elevation decreased. UFR: ultrafiltration
rate. UF: ultrafiltration. ECUM: extracorporeal ultrafiltration method. All values are expressed as mean ± SD. *P < 0.01. **P < 0.05
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sixth month (from 18 to 12 patients), but showing no
statistical difference from PS/PES group (Table 2).
Of note, there were no significant differences in pre--
dialysis body weight, ultrafiltration volume, CTR
between both groups and no changes in the number of
patients who used antihypertensive drugs or antiplatelet/
anticoagulant drugs in both groups during the whole
study period (Table 3).
Patients’ clinical characteristics at sixth month
Table 4 shows the data including the markers of nutri-
tional states, mineral-bone disorder, anemia, lipid, ar-
teriosclerosis, inflammation, and catecholamine at sixth
month (the end of comparative period). There were no
significant differences between two groups. These results
indicated that nutritional status was similar between
both groups and the therapy targets for anemia and
mineral-bone disorder were commonly recognized in
every dialysis center. NV group did not receive advanta-
geous effects on arteriosclerosis and inflammation
markers compared to PS/PES group at sixth month.
Differences between NV non-responders and responders
From the 18 patients in NV group with average SBP fall
over 30 mmHg in 1 month in pre-observation period,
we divided 12 patients as NV non-responders whose
SBP falls remained over 30 mmHg at sixth month and 6
patients as NV responders whose SBP falls decreased no
more than 30 mmHg at sixth month (Table 2). Between
the two groups, we examined the statistical difference of
various parameters at zero month. Then, NV responders
had significantly longer dialysis vintages, lower body
weights, lower potassium and higher HDL cholesterol
levels than NV non-responders. NV responders also had
lower body mass indexes, higher ferritin and hsCRP
levels, but not reaching significant difference (Table 5).
Regarding PS group, we were not able to analyze the
difference between non-responders and responders sta-
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Fig. 3 Systolic blood pressure in NV and PS/PES groups. a–c In pre-observation period, there were no differences in pre-dialysis, post-dialysis, and
lowest systolic blood pressure (SBP) between NV and PS/PES groups. However, in NV group, post-dialysis and the lowest SBP were significantly
higher at sixth month compared to those in PS/PES group. d The average value of SBP fall during hemodialysis was significantly relieved in NV
group at sixth month compared as that in pre-observation period, while SBP fall was not improved in PS/PES group. All values are expressed as
mean ± SD. *P < 0.01. **P < 0.05
Table 2 The number of patients with average systolic blood
pressure fall over 30 mmHg in 1 month
Pre-observation period (zero month) Sixth month
NV group > 30 mmHg 18 > 30 mmHg 12a
≤ 30 mmHg 6b
≤ 30 mmHg 2 > 30 mmHg 0
≤ 30 mmHg 2
PS/PES group > 30 mmHg 14 > 30 mmHg 13
≤ 30 mmHg 1
≤ 30 mmHg 6 > 30 mmHg 1
≤ 30 mmHg 5
aNV non-responders
bNV responders
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Discussion
In this study, we demonstrated that NV dialyzers
increased post-dialysis and the lowest SBP compared as
conventional PS/PES dialyzers, even though the total
number of treatments for IDH decreased. The reduction
of intervention for IDH correlated with the increase of
SBP during HD. It gives validity to the results and
supports the usefulness of NV as a possible method to
deal with IDH.
Intradialytic blood pressure was controlled by complex
mechanisms. Many factors including dry weight setting,
ultrafiltration rate, nutritional status, anemia, and in-
flammation are involved in the maintenance of blood
pressure during HD. Therefore, it is really difficult to es-
timate the effects of new equipment on the improve-
ment of IDH. We intervened IDH by using hydrophilic
polymer-coated PS membrane NV dialyzers. NV could
reduce the number of treatments for IDH and improve
intradialytic SBP (Figs. 2 and 3), even though representa-
tive influential factors on IDH such as pre-dialysis body
weight, ultrafiltration rate were similar during the whole
study period (Table 3). In addition, the number of pa-
tients with average SBP fall over 30 mmHg in 1 month
Table 3 Changes in parameters related to IDH
NV group PS/PES group P
Pre-dialysis body weight (kg)
Pre-observation period (zero month) 66.7 ± 17.5 67.7 ± 12.4 0.84
First month 66.7 ± 17.4 67.9 ± 12.4 0.81
Second month 66.7 ± 17.5 67.8 ± 12.4 0.83
Third month 66.9 ± 17.6 68.1 ± 12.6 0.80
Fourth month 66.8 ± 17.6 68.0 ± 12.5 0.81
Fifth month 66.6 ± 17.6 67.8 ± 12.7 0.81
Sixth month 66.6 ± 17.5 68.1 ± 13.1 0.76
Ultrafiltration volume (ml/session)
Pre-observation period (zero month) 3071 ± 1134 3163 ± 996 0.79
First month 3014 ± 1173 3066 ± 985 0.88
Second month 2939 ± 1168 2988 ± 964 0.89
Third month 2949 ± 1201 3129 ± 1015 0.61
Fourth month 2995 ± 1171 3015 ± 1005 0.95
Fifth month 3023 ± 1305 2956 ± 1020 0.86
Sixth month 3028 ± 1202 3134 ± 1018 0.77
Cardiothoracic ratio (%)
Pre-observation period (zero month) 50.1 ± 4.9 50.7 ± 5.3 0.72
Sixth month 51.4 ± 4.5 52.1 ± 5.6 0.69
Antihypertensive drug users (%)
Pre-observation period (zero month) 16 (80%) 9 (45%) 0.02
ARB (8) ARB (5)
Ca antag. (13) Ca antag. (4)
β blocker (3) β blocker (3)
α blocker (1) α blocker (1)
αβ blocker (1) αβ blocker (2)
Sixth month 17 (85%) 10 (50%) 0.02
ARB (7) ARB (6)
Ca antag. (13) Ca antag. (5)
β blocker (1) β blocker (4)
α blocker (3) α blocker (1)
αβ blocker (1) αβ blocker (2)
Antiplatelet/anticoagulant users (%)a
Pre-observation period (zero month) 14 (82%) 17 (100%) 0.23
Aspirin (12) Aspirin (15)
Clopidogrel (1) Clopidogrel (2)
Warfarin (0) Warfarin (3)
EPA (0) EPA(0)
O3FAE (0) O3FAE (0)
Other (3) Other (6)
Statin (1) Statin (3)
Sixth month 14 (82%) 17 (100%) 0.23
Aspirin (12) Aspirin (15)
Clopidogrel (3) Clopidogrel (3)
Warfarin (1) Warfarin (2)
EPA (0) EPA (0)
O3FAE (0) O3FAE (0)
Other (3) Other (7)
Statin (1) Statin (3)
ARB angiotensin receptor blocker, Ca antag. calcium antagonist, EPA Epadel, O3FAE,
Omega-3-fatty acid ethyl esters, Other Other antiplatelet/anticoagulant
an = 17 in both NV and PS/PES groups
Table 4 Patients’ clinical characteristics at sixth month
NV group PS/PES group P
BMI (kg/m2) 24.0 ± 5.0 24.8 ± 4.2 0.57
White blood cell count (×103/μL) 6.1 ± 2.0 6.7 ± 2.3 0.37
Hemoglobin (g/dL) 10.6 ± 2.5 10.8 ± 0.9 0.75
Platelet (×104/μL) 18.6 ± 5.0 18.2 ± 4.7 0.84
ESA user (%) 16 (80%) 15 (75%) 0.71
Ferritin (ng/mL) 104.6 ± 88.1 88.3 ± 55.6 0.50
Phosphate (mg/dL) 5.8 ± 1.1 5.2 ± 0.9 0.10
Calcium (mg/dL) 8.9 ± 0.7 8.9 ± 0.6 1.00
Intact PTH (ng/mL) 154 ± 121 161 ± 152 0.87
Albumin (g/dL) 3.5 ± 0.3 3.5 ± 0.2 0.96
Total-cholesterol (mg/dL) 169 ± 31 157 ± 29 0.20
Triglyceride (mg/dL) 119 ± 60 155 ± 115 0.22
HDL-cholesterol (mg/dL) 45 ± 12 45 ± 13 0.92
Ankle brachial index (right) 1.00 ± 0.28 1.11 ± 0.25 0.33
Ankle brachial index (left) 1.00 ± 0.28 1.08 ± 0.23 0.33
Homocysteine (nmol/mL) 34.5 ± 17.6 29.6 ± 12.0 0.31
Pentosidine (μg/mL) 0.399 ± 0.177 0.351 ± 0.184 0.40
hsCRP (mg/dL) 0.179 ± 0.191 0.212 ± 0.201 0.60
Pentraxin 3 (ng/mL) 4.47 ± 2.12 3.71 ± 2.51 0.31
Adrenaline (ng/mL) 0.02 ± 0.01 0.02 ± 0.01 0.81
Noradrenaline (ng/mL) 0.44 ± 0.24 0.41 ± 0.19 0.73
Dopamine (ng/mL) 0.04 ± 0.02 0.06 ± 0.04 0.15
BMI body mass index, ESA erythropoiesis-stimulating agent, HDL high-density
lipoprotein, hsCRP high-sensitivity C-reactive protein
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decreased significantly at sixth month in NV group
(Table 2). However, we could not find the significant
difference of clinical characteristics that can be related
to blood pressure control between NV and PS/PES
groups (Table 4). Therefore, NV could show preferable
effects to manage IDH compared to conventional PS/
PES dialyzers, even though the mechanism of advanta-
geous effects on IDH by NV has not been clarified yet.
The reason why NV showed several advantages over
PS/PES dialyzers is still unknown. The values of ejection
fraction were significantly higher in NV group than
those in PS/PES group (Table 1), though it was not suffi-
cient to explain NV advantage in avoiding hypotension
because pulse rates in NV group were not increased
after HD and not different from those in PS/PES groups
at sixth month (data not shown). In addition, there was
no difference of ejection fraction values between NV
non-responders and responders (Table 5). In our study,
the improvement of IDH by NV dialyzers appeared at
later time points in comparative period. In addition to
pre-dialysis body weight and ultrafiltration volume,
nutritional status was similar during the whole study
period. Therefore, we guess that NV played some indir-
ect roles to improve peripheral vascular response to
volume depletion during HD. Hidaka et al. showed that
three-month HD using NV increased flow-mediated
dilatation of the brachial artery, which suggested the







Patients (n) 12 6
Age (years) 60.8 ± 11.6 64.7 ± 1.8 0.43
Female (%) 3 (25%) 3 (50%) 0.31




10 (83%) 5 (83%) 1
ARB (3) ARB (3)
Ca antag. (8) Ca antag. (3)
β blocker (1) β blocker (2)
α blocker (0) α blocker (1)
αβ blocker (1) αβ blocker (0)
Antiplatelet/anticoagulant
users (%)a
7 (70%) 5 (100%) 0.49





O3FAE (0) O3FAE (0)
Other (1) Other (2)
Statin (0) Statin (1)
Ejection fraction (%)a 70.2 ± 5.5 71.5 ± 5.4 0.69
Comorbidities
Ischemic heart disease (%)a
2 (20%) 3 (60%) 0.33
Heart failure (%)a 3 (30%) 2 (40%) 0.85
Cerebral infarction (%)a 1 (10%) 2 (40%) 0.49
Cerebral hemorrhage (%)a 0 (0%) 0 (0%) 1
BMI (kg/m2) 25.8 ± 5.1 20.7 ± 4.1 0.05
White blood cell count
(×103/μL)
6.43 ± 1.73 6.47 ± 2.16 0.91
Hemoglobin (g/dL) 11.5 ± 0.9 11.0 ± 0.3 0.33
Platelet (×104/μL) 20.5 ± 5.9 20.0 ± 4.3 0.93
ESA user (%) 67% 50% 0.86
Ferritin (ng/mL) 77 ± 68 205 ± 227 0.08
Sodium (mEq/L) 138 ± 2 139 ± 2 0.37
Potassium (mEq/L) 5.5 ± 0.8 4.5 ± 0.9 0.02
Phosphate (mg/dL) 6.1 ± 1.6 5.3 ± 1.0 0.24
Calcium (mg/dL) 9.0 ± 0.7 9.4 ± 0.8 0.29
Intact PTH (ng/mL) 148 ± 105 77 ± 80 0.17
Albumin (g/dL) 3.6 ± 0.3 3.5 ± 0.2 0.55
Total-cholesterol (mg/dL) 168 ± 38 175 ± 39 0.71
Triglyceride (mg/dL) 127 ± 73 95 ± 53 0.53
HDL-cholesterol (mg/dL) 38 ± 10 56 ± 13
Table 5 Demographic and clinical characteristics of NV








Ankle brachial index (right) 1.06 ± 0.25 0.94 ± 0.27 0.40
Ankle brachial index (left) 1.12 ± 0.17 1.10 ± 0.26 0.85
Homocysteine (nmol/mL) 32.6 ± 16.0 46.4 ± 39.8 0.30
Pentosidine (μg/mL) 0.46 ± 0.23 0.39 ± 0.19 0.54
hsCRP (mg/dL) 0.17 ± 0.17 0.34 ± 0.17 0.06
Pentraxin 3 (ng/mL) 3.77 ± 1.40 5.00 ± 2.08 0.15
Adrenaline (ng/mL) 0.018 ± 0.009 0.022 ± 0.012 0.40
Noradrenaline (ng/mL) 0.34 ± 0.21 0.38 ± 0.11 0.69
Dopamine (ng/mL) 0.033 ± 0.018 0.043 ± 0.021 0.26
Pre-dialysis body weight (kg) 74.4 ± 17.1 54.0 ± 8.6 0.02
Post-dialysis body weight
(kg)
71.1 ± 16.1 51.2 ± 8.8 0.01
Ultrafiltration volume
(ml/session)
3604 ± 1234 2693 ± 607 0.11
Cardiothoracic ratio (%) 51.4 ± 5.1 48.3 ± 4.7 0.24
ARB angiotensin receptor blocker, Ca antag. calcium antagonist, EPA epadel,
O3FAE omega-3-fatty acid ethyl esters, Other other antiplatelet/anticoagulant,
BMI body mass index, ESA erythropoiesis-stimulating agent, HDL high-density
lipoprotein, hsCRP high-sensitivity C-reactive protein
an = 10 in NV non-responders and n = 5 in NV responders
Tsuchida et al. Renal Replacement Therapy  (2017) 3:58 Page 8 of 10
improvement of endothelial dysfunction [15]. The con-
tinuous use of NV could improve the dysfunction of vas-
cular endothelial cells and reduce the number of IDH.
Recently, Kakuta et al. demonstrated that NV dialyzer
induces less IL-6 than the conventional dialyzers, but
pre-dialysis IL-6 values did not change during 1-year
observation period [23]. Plasma IL-6 levels were re-
ported to influence the severity of arterial wall stiffness
in chronic kidney disease patients [24]. Therefore, the
long-term use of NV might suppress the progression of
arteriosclerosis, resulted in decrease in the number of
IDH. NV responders had significantly longer dialysis
vintages, lower body weights, lower potassium, and
higher HDL cholesterol levels than non-responders. NV
responders also had lower body mass indexes, higher
ferritin and hsCRP levels, but not reaching significant
difference. Thus, NV responders possessed valuables
suggesting malnutrition and microinflammation, and
better lipid profiles (Table 5). NV responders had similar
characteristics including low ankle brachial index as the
dialysis patients with peripheral artery disease do [25, 26],
which can evoke better response to NV treatment.
Consequently, our hypothesis about the role of “bio-
compatibility” of NV is as follows. Dialysis membrane
surface is made hydrophilic. The activations of platelets
and white blood cells during HD are suppressed,
followed by decreased production of microparticles
derived from activated platelets [15] and inflammatory
cytokines [23]. Thus, microinflammation and oxidative
stress production during HD are relieved. Endothelial
cell function is improved and the vasoconstriction
response to hypotention is recovered during HD. How-
ever, relevant factors should be investigated to clarify the
mechanism of NV effects on hemodynamic status.
In our study, we failed to find significant alterations of
inflammation markers such as hsCRP and PTX3 in NV
group and significant differences of them compared to
PS/PES group. As Kakuta et al. did, we may have to
focus on the alteration of these parameters during HD.
We also should have monitored the vascular response
such as flow-mediated dilatation of the brachial artery,
orthostatic hypotension, or skin perfusion pressure,
more sensitive marker to detect peripheral artery disease
than ankle brachial index, to clarify the NV effects on
IDH [27].
Kakuta et al. also reported that NV dialyzer would
reduce the risk of erythropoiesis-stimulating agent hypo-
responsiveness by inducing less IL-6 production during
HD in patients with high IL-6 concentrations than the
conventional dialyzers. NV group in our study did not
have an improvement of anemia management (Tables 1
and 4). Our enrolled subjects did not have high values of
hsCRP and PTX3. NV effects on the improvement of
anemia control would be limited to the patients with
inflammation-related erythropoiesis-stimulating agent
hypo-responsiveness.
A weakness of this study is its relatively small sample
size that could cause unknown source of bias in the
findings. The other limitation is that dialyzers for control
patients were not limited to PS only, to avoid too much
interference to hypotension-prone patients.
Conclusions
In summary, this prospective stratified-randomized
multicenter study compared the number of treatments
for IDH in DN HD patients between NV and PS/PES
dialysis users. Post-dialysis SBP and the lowest SBP dur-
ing HD became significantly higher in NV group than
those in PS/PES group. In addition, the total number of
treatments for IDH was significantly decreased in NV
group. Thus, NV prevented IDH in DN patients under-
going HD. NV responders possessed valuables suggest-
ing malnutrition and microinflammation. Further studies
are needed to clarify the NV effect on IDH.
Additional file
Additional file 1: Dialyzers of NV group. (PDF 65 kb)
Additional file 2: Dialyzers of PS/PES group. (PDF 57 kb)
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